[Antitumor effect of adriamycin conjugated with downsized anti-endoglin monclonal antibody].
OBJECTIVE
To study the antitumor efficacy of an immunoconjugate composed of adriamycin (ADM) and downsized Fab fragment of mouse anti-Endoglin monoclonal antibody.


METHODS
The Fab fragment of mouse anti-Endoglin monoclonal antibody was downsized and conjugated with ADM by m-Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). The antitumor effect of the conjugate was tested in mice bearing subcutaneous injection of H22 tumor in vivo.


RESULTS
The molecular ratio of Fab:ADM in conjugate was approximately 1:2. The Fab-ADM conjugate inhibited the growth of H22 by 91.94% on day 14 after injection at the dose of 0.4 mg/ kg, much higher the inhibition rate of 25.00% by the equivalent dose of free ADM. The median survival time of the mice treated with the conjugate was longer than those treated with free ADM. The Fab-ADM conjugate was significantly more effective than free ADM in tumor suppression and life span prolongation.


CONCLUSIONS
Fab -ADM displayed more significant antitumor efficacy than free ADM in vivo and might be a novel candidate for cancer treatment.
Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical College, Haikou 571101, China.
Ling
L
Li
Feng-ying
FY
Huang
Yong-hao
YH
Huang
Song-lin
SL
Zhou
Jun-li
JL
Guo
Huan-ge
HG
Zhao
Guang-hong
GH
Tan
Hua
H
Wang
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology*; D000071063:Endoglin; D000922:Immunotoxins / Q000494:pharmacology*; D047908:Intracellular Signaling Peptides and Proteins / Q000276:immunology*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D000071063:Endoglin; C502004:Eng protein, mouse; D000922:Immunotoxins; D047908:Intracellular Signaling Peptides and Proteins; D004317:Doxorubicin